Meeting
2024 ASCO Annual Meeting
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
Authors
Jung-Yun Lee
Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea
Jung-Yun Lee , Baek-Yeol Ryoo , Jin Won Kim , Ann-Lii Cheng , Richard S. Finn , Kosei Hasegawa , Vicky Makker , Masatoshi Kudo , David Scott Miller , Philippe Merle , Susanna Varkey Ulahannan , Tetsuya Hosaka , Takatoshi Sahara , Cixin S. He , Karen O'Hara , Lea Dutta , Toshiyuki Tamai , Masafumi Ikeda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04008797
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS3169)
DOI
10.1200/JCO.2024.42.16_suppl.TPS3169
Abstract #
TPS3169
Poster Bd #
309b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist.
First Author: Heather Metz
Poster
2024 ASCO Annual Meeting
Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.
First Author: Kerin B. Adelson
Poster
2024 ASCO Annual Meeting
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H.
First Author: April K.S. Salama
Poster
2024 ASCO Annual Meeting
Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.
First Author: Susanna Varkey Ulahannan